Recurrent or Metastatic Breast Cancer Clinical Trial
Official title:
Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer
SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.
The purpose of this study is to evaluate level of test medication with respect to time in the body, and safety when compared with the reference medication Subject will be randomly assigned to receive an intravenous infusion of either SPARC1613 delivered over 25 (±1) minutes or Reference1613 delivered over 30 (±1) minutes ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03947736 -
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
|
||
| Completed |
NCT03326102 -
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03315364 -
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
|
Phase 2/Phase 3 |